Clinical trial
Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
NCT00473343 · Galderma R&D, Industry · Completed
Key facts
| NCT number | NCT00473343 |
|---|---|
| Title | Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma |
| Official title | An Open Multicenter, Phase III Study of Photodynamic Therapy With Metvix® Cream 160 mg/g in Patients With "High Risk" Basal Cell Carcinoma |
| Lead sponsor | Galderma R&D, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Basal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Metvix® cream |
| Enrollment | 102 |
| Start date | Sep 1, 2000 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | May 15, 2007 |
| Last update posted | Jan 5, 2023 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: